Lyra Therapeutics Announces Material Definitive Agreement

Ticker: LYRA · Form: 8-K · Filed: Jun 27, 2025 · CIK: 1327273

Lyra Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyLyra Therapeutics, INC. (LYRA)
Form Type8-K
Filed DateJun 27, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-definitive-agreement, equity-sale, other-events

TL;DR

Lyra Therapeutics signed a material definitive agreement on 6/26, expect news.

AI Summary

Lyra Therapeutics, Inc. announced on June 26, 2025, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securities and other events. The filing was made on June 27, 2025.

Why It Matters

This filing indicates a significant new agreement for Lyra Therapeutics, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities that may affect the company's stock price.

Key Players & Entities

FAQ

What is the nature of the Material Definitive Agreement entered into by Lyra Therapeutics?

The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on June 26, 2025.

What type of equity securities were sold in the unregistered sale?

The filing mentions unregistered sales of equity securities but does not provide specific details about the type or amount.

Are there any other significant events reported in this 8-K filing?

Besides the Material Definitive Agreement and unregistered sales of equity securities, the filing also lists 'Other Events' and 'Financial Statements and Exhibits' as items of disclosure.

What is Lyra Therapeutics' fiscal year end?

Lyra Therapeutics' fiscal year ends on December 31.

What is Lyra Therapeutics' business address?

Lyra Therapeutics' business address is 480 Arsenal Way, Watertown, MA 02472.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 27, 2025 regarding Lyra Therapeutics, Inc. (LYRA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing